# Hewlett Packard Enterprise Co: financial statements, quarterly

HPE · NYSE · CIK 1645590 · [Technology](/sectors/technology.md) · fiscal year ends Oct 31

Pages: [Overview](/companies/hpe.md) · [Financials](/companies/hpe/financials.md) · [Filings](/companies/hpe/filings.md) · [Insiders](/companies/hpe/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/hpe/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [7.4 d](/filings/0001645590-25-000130.md) | [6.8](/filings/0001645590-25-000039.md) | [7.2](/filings/0001645590-25-000068.md) | [7.7](/filings/0001645590-25-000101.md) | [8.5 d](/filings/0001645590-25-000130.md) | [7.9](/filings/0001645590-26-000032.md) | [7.6](/filings/0001645590-26-000055.md) | [9.1](/filings/0001645590-26-000080.md) | [9.7 d](/filings/0001645590-25-000130.md) | [9.3](/filings/0001645590-26-000032.md) | [10.7](/filings/0001645590-26-000055.md) | [12.2](/filings/0001645590-26-000080.md) |
| Cost of revenue | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $bn | [0.6 d](/filings/0001645590-25-000130.md) | [0.6](/filings/0001645590-25-000039.md) | [0.6](/filings/0001645590-25-000068.md) | [0.5](/filings/0001645590-25-000101.md) | [0.5 d](/filings/0001645590-25-000130.md) | [0.5](/filings/0001645590-26-000032.md) | [0.5](/filings/0001645590-26-000055.md) | [0.6](/filings/0001645590-26-000080.md) | [0.9 d](/filings/0001645590-25-000130.md) | [0.7](/filings/0001645590-26-000032.md) | [0.9](/filings/0001645590-26-000055.md) | [1.2](/filings/0001645590-26-000080.md) |
| Selling, general and administrative | $bn | [1.3 d](/filings/0001645590-25-000130.md) | [1.2](/filings/0001645590-25-000039.md) | [1.2](/filings/0001645590-25-000068.md) | [1.2](/filings/0001645590-25-000101.md) | [1.2 d](/filings/0001645590-25-000130.md) | [1.3](/filings/0001645590-26-000032.md) | [1.3](/filings/0001645590-26-000055.md) | [1.5](/filings/0001645590-26-000080.md) | [1.6 d](/filings/0001645590-25-000130.md) | [1.7](/filings/0001645590-26-000032.md) | [1.8](/filings/0001645590-26-000055.md) | [2.0](/filings/0001645590-26-000080.md) |
| Operating income | $bn | [0.5 d](/filings/0001645590-25-000130.md) | [0.5](/filings/0001645590-25-000039.md) | [0.4](/filings/0001645590-25-000068.md) | [0.5](/filings/0001645590-25-000101.md) | [0.7 d](/filings/0001645590-25-000130.md) | [0.4](/filings/0001645590-26-000032.md) | [(1.1)](/filings/0001645590-26-000055.md) | [0.2](/filings/0001645590-26-000080.md) | [(0.0) d](/filings/0001645590-25-000130.md) | [0.5](/filings/0001645590-26-000032.md) | [0.7](/filings/0001645590-26-000055.md) | [1.4](/filings/0001645590-26-000080.md) |
| Interest expense | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $bn | [(0.1) d](/filings/0001645590-25-000130.md) | [0.1](/filings/0001645590-25-000039.md) | [0.1](/filings/0001645590-25-000068.md) | [0.1](/filings/0001645590-25-000101.md) | [0.1 d](/filings/0001645590-25-000130.md) | [0.1](/filings/0001645590-26-000032.md) | [0.0](/filings/0001645590-26-000055.md) | [(0.0)](/filings/0001645590-26-000080.md) | [(0.4) d](/filings/0001645590-25-000130.md) | [(0.0)](/filings/0001645590-26-000032.md) | [0.1](/filings/0001645590-26-000055.md) | [0.2](/filings/0001645590-26-000080.md) |
| Net income | $bn | [0.6 d](/filings/0001645590-25-000130.md) | [0.4](/filings/0001645590-25-000039.md) | [0.3](/filings/0001645590-25-000068.md) | [0.5](/filings/0001645590-25-000101.md) | [1.4 d](/filings/0001645590-25-000130.md) | [0.6](/filings/0001645590-26-000032.md) | [(1.1)](/filings/0001645590-26-000055.md) | [0.3](/filings/0001645590-26-000080.md) | [0.2 d](/filings/0001645590-25-000130.md) | [0.5](/filings/0001645590-26-000032.md) | [0.6](/filings/0001645590-26-000055.md) | [1.5](/filings/0001645590-26-000080.md) |
| Diluted EPS | $ per share | not reported | [0.29](/filings/0001645590-25-000039.md) | [0.24](/filings/0001645590-25-000068.md) | [0.38](/filings/0001645590-25-000101.md) | not reported | [0.44](/filings/0001645590-26-000032.md) | [(0.82)](/filings/0001645590-26-000055.md) | [0.21](/filings/0001645590-26-000080.md) | not reported | [0.31](/filings/0001645590-26-000032.md) | [0.44](/filings/0001645590-26-000055.md) | [1.06](/filings/0001645590-26-000080.md) |
| Basic EPS | $ per share | not reported | [0.30](/filings/0001645590-25-000039.md) | [0.24](/filings/0001645590-25-000068.md) | [0.39](/filings/0001645590-25-000101.md) | not reported | [0.45](/filings/0001645590-26-000032.md) | [(0.82)](/filings/0001645590-26-000055.md) | [0.21](/filings/0001645590-26-000080.md) | not reported | [0.32](/filings/0001645590-26-000032.md) | [0.45](/filings/0001645590-26-000055.md) | [1.13](/filings/0001645590-26-000080.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [4.3](/filings/0001645590-24-000139.md) | [3.8](/filings/0001645590-24-000069.md) | [2.7](/filings/0001645590-24-000098.md) | [3.6](/filings/0001645590-24-000119.md) | [14.8](/filings/0001645590-25-000130.md) | [13.4](/filings/0001645590-25-000039.md) | [11.7](/filings/0001645590-25-000068.md) | [4.6](/filings/0001645590-25-000101.md) | [5.8](/filings/0001645590-26-000080.md) | [4.8](/filings/0001645590-26-000032.md) | [5.3](/filings/0001645590-26-000055.md) | [6.2](/filings/0001645590-26-000080.md) |
| Current assets | $bn | [18.9](/filings/0001645590-24-000139.md) | [20.2](/filings/0001645590-24-000069.md) | [21.4](/filings/0001645590-24-000098.md) | [22.4](/filings/0001645590-24-000119.md) | [33.5](/filings/0001645590-25-000130.md) | [33.0](/filings/0001645590-25-000039.md) | [31.6](/filings/0001645590-25-000068.md) | [26.0](/filings/0001645590-25-000101.md) | [25.0](/filings/0001645590-26-000080.md) | [25.2](/filings/0001645590-26-000032.md) | [29.4](/filings/0001645590-26-000055.md) | [33.9](/filings/0001645590-26-000080.md) |
| Total assets | $bn | [57.2](/filings/0001645590-24-000139.md) | [58.6](/filings/0001645590-24-000069.md) | [59.7](/filings/0001645590-24-000098.md) | [60.9](/filings/0001645590-24-000119.md) | [71.3](/filings/0001645590-25-000130.md) | [70.3](/filings/0001645590-25-000039.md) | [67.9](/filings/0001645590-25-000068.md) | [77.3](/filings/0001645590-25-000101.md) | [75.9](/filings/0001645590-26-000080.md) | [75.8](/filings/0001645590-26-000032.md) | [79.5](/filings/0001645590-26-000055.md) | [83.6](/filings/0001645590-26-000080.md) |
| Current liabilities | $bn | [21.9](/filings/0001645590-24-000139.md) | [22.6](/filings/0001645590-24-000069.md) | [23.8](/filings/0001645590-24-000098.md) | [23.9](/filings/0001645590-24-000119.md) | [26.0](/filings/0001645590-25-000130.md) | [24.9](/filings/0001645590-25-000039.md) | [24.5](/filings/0001645590-25-000068.md) | [27.3](/filings/0001645590-25-000101.md) | [24.6](/filings/0001645590-26-000080.md) | [24.4](/filings/0001645590-26-000032.md) | [27.0](/filings/0001645590-26-000055.md) | [30.4](/filings/0001645590-26-000080.md) |
| Total liabilities | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $bn | [7.5](/filings/0001645590-24-000119.md) | [7.8](/filings/0001645590-24-000069.md) | [7.5](/filings/0001645590-24-000098.md) | [7.9](/filings/0001645590-24-000119.md) | [13.5](/filings/0001645590-25-000101.md) | [13.3](/filings/0001645590-25-000039.md) | [12.4](/filings/0001645590-25-000068.md) | [16.9](/filings/0001645590-25-000101.md) | [17.8](/filings/0001645590-26-000080.md) | [17.7](/filings/0001645590-26-000032.md) | [18.2](/filings/0001645590-26-000055.md) | [17.3](/filings/0001645590-26-000080.md) |
| Current portion of debt | $bn | [4.0](/filings/0001645590-24-000139.md) | [4.1](/filings/0001645590-24-000069.md) | [3.0](/filings/0001645590-24-000098.md) | [3.1](/filings/0001645590-24-000119.md) | [4.0](/filings/0001645590-25-000130.md) | [3.8](/filings/0001645590-25-000039.md) | [4.4](/filings/0001645590-25-000068.md) | [5.1](/filings/0001645590-25-000101.md) | [3.8](/filings/0001645590-26-000080.md) | [3.1](/filings/0001645590-26-000032.md) | [2.2](/filings/0001645590-26-000055.md) | [2.1](/filings/0001645590-26-000080.md) |
| Short-term borrowings | $bn | [4.9](/filings/0001645590-24-000139.md) | [0.7](/filings/0001645590-24-000069.md) | [0.6](/filings/0001645590-24-000098.md) | [0.6](/filings/0001645590-24-000119.md) | [4.7](/filings/0001645590-25-000130.md) | not reported | not reported | not reported | [4.6](/filings/0001645590-25-000130.md) | not reported | not reported | not reported |
| Shareholders' equity | $bn | [21.2](/filings/0001645590-24-000139.md) | [21.4](/filings/0001645590-24-000069.md) | [21.7](/filings/0001645590-24-000098.md) | [22.1](/filings/0001645590-24-000119.md) | [24.8](/filings/0001645590-25-000130.md) | [25.2](/filings/0001645590-25-000039.md) | [23.9](/filings/0001645590-25-000068.md) | [24.4](/filings/0001645590-25-000101.md) | [24.7](/filings/0001645590-26-000080.md) | [24.8](/filings/0001645590-26-000032.md) | [25.3](/filings/0001645590-26-000055.md) | [26.5](/filings/0001645590-26-000080.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings, us-gaap:CommercialPaper
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-10-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q4 FY2024 (2024-10-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q4 FY2025 (2025-10-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [2,843 d](/filings/0001645590-25-000130.md) | [64.0](/filings/0001645590-25-000039.md) | [1,093 d](/filings/0001645590-25-000068.md) | [1,154 d](/filings/0001645590-25-000101.md) | [2,030 d](/filings/0001645590-25-000130.md) | [(390)](/filings/0001645590-26-000032.md) | [(461) d](/filings/0001645590-26-000055.md) | [1,305 d](/filings/0001645590-26-000080.md) | [2,465 d](/filings/0001645590-25-000130.md) | [1,178](/filings/0001645590-26-000032.md) | [1,410 d](/filings/0001645590-26-000055.md) | [1,641 d](/filings/0001645590-26-000080.md) |
| Capital expenditure | $m | [675 d](/filings/0001645590-25-000130.md) | [656](/filings/0001645590-25-000039.md) | [560 d](/filings/0001645590-25-000068.md) | [543 d](/filings/0001645590-25-000101.md) | [608 d](/filings/0001645590-25-000130.md) | [528](/filings/0001645590-26-000032.md) | [547 d](/filings/0001645590-26-000055.md) | [576 d](/filings/0001645590-26-000080.md) | [641 d](/filings/0001645590-25-000130.md) | [569](/filings/0001645590-26-000032.md) | [583 d](/filings/0001645590-26-000055.md) | [745 d](/filings/0001645590-26-000080.md) |
| Dividends paid | $m | [154 d](/filings/0001645590-25-000130.md) | [169](/filings/0001645590-25-000039.md) | [169 d](/filings/0001645590-25-000068.md) | [169 d](/filings/0001645590-25-000101.md) | [169 d](/filings/0001645590-25-000130.md) | [171](/filings/0001645590-26-000032.md) | [171 d](/filings/0001645590-26-000055.md) | [171 d](/filings/0001645590-26-000080.md) | [171 d](/filings/0001645590-25-000130.md) | [190](/filings/0001645590-26-000032.md) | [189 d](/filings/0001645590-26-000055.md) | [189 d](/filings/0001645590-26-000080.md) |
| Share repurchases | $m | [55.0 d](/filings/0001645590-25-000130.md) | [3.0](/filings/0001645590-25-000039.md) | [45.0 d](/filings/0001645590-25-000068.md) | [52.0 d](/filings/0001645590-25-000101.md) | [50.0 d](/filings/0001645590-25-000130.md) | [52.0](/filings/0001645590-26-000032.md) | [50.0 d](/filings/0001645590-26-000055.md) | [0.0 d](/filings/0001645590-26-000080.md) | [100 d](/filings/0001645590-25-000130.md) | [158](/filings/0001645590-26-000032.md) | [154 d](/filings/0001645590-26-000055.md) | [135 d](/filings/0001645590-26-000080.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-01-31) | Q2 FY2023 (2023-04-30) | Q3 FY2023 (2023-07-31) | Q1 FY2024 (2024-01-31) | Q2 FY2024 (2024-04-30) | Q3 FY2024 (2024-07-31) | Q1 FY2025 (2025-01-31) | Q2 FY2025 (2025-04-30) | Q3 FY2025 (2025-07-31) | Q1 FY2026 (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1,315](/filings/0001645590-24-000069.md) | [1,318](/filings/0001645590-24-000098.md) | [1,316](/filings/0001645590-24-000119.md) | [1,316](/filings/0001645590-25-000039.md) | [1,325](/filings/0001645590-25-000068.md) | [1,332](/filings/0001645590-25-000101.md) | [1,409](/filings/0001645590-26-000032.md) | [1,322](/filings/0001645590-26-000055.md) | [1,421](/filings/0001645590-26-000080.md) | [1,356](/filings/0001645590-26-000032.md) | [1,432](/filings/0001645590-26-000055.md) | [1,449](/filings/0001645590-26-000080.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,327,464,779 at 2026-08-27, from the cover of the [10-Q filed 2026-09-03](/filings/0001645590-26-000080.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.